Injectable cyanocobalamin is a prescription medicine with labelled warnings. This page summarises what that label and the clinical literature report; it is not medical advice and does not replace a clinician's judgement.
Overview
B12's safety reputation is deserved. It is water-soluble, the body does not store the excess, and the Food and Nutrition Board declined to set a Tolerable Upper Intake Level "because of its low potential for toxicity" (NIH Office of Dietary Supplements). That is an unusually strong statement, and it is the reason 5,000 mcg products exist without an obvious toxicological objection.
But "no upper limit" is not the same as "no warnings." The FDA-labelled injectable form carries three that are specific rather than boilerplate, and they concentrate in exactly the situation where B12 is most likely to be used — a genuinely deficient patient being treated.
The three warnings that are not generic
From the cyanocobalamin injection label (DailyMed):
Hypokalaemia and sudden death. The label states that "hypokalaemia and sudden death may occur in severe megaloblastic anaemia which is treated intensely." The mechanism is that rapid red-cell production draws potassium into new cells, dropping serum potassium. This is the single strongest argument for treating significant deficiency under medical supervision with monitoring rather than on one's own.
Early Leber's disease. Patients with early Leber's disease — hereditary optic nerve atrophy — treated with cyanocobalamin "suffered severe and swift optic atrophy." This is a specific contraindication-level concern tied to the cyanide moiety in cyanocobalamin, and it is one reason hydroxocobalamin is preferred in some settings.
Anaphylaxis. "Anaphylactic shock and death have been reported after parenteral vitamin B12 administration." Rare, but the reason injections are given where a reaction can be managed.
Sensitivity to cobalt or to vitamin B12 itself is a listed contraindication. Formulations preserved with benzyl alcohol carry the separate warning about fatal "gasping syndrome" in premature infants, and products containing aluminium may accumulate to toxic levels with prolonged use in impaired renal function.
Reported adverse reactions
The label's adverse reaction list spans the mild and the serious: mild transient diarrhoea, itching, transitory exanthema, and a feeling of swelling of the entire body at one end; anaphylactic shock and death, pulmonary oedema and congestive heart failure early in treatment, peripheral vascular thrombosis, and polycythaemia vera at the other. Local injection-site pain, redness, swelling or itching are the ordinary practical effects.
In the comparative literature, tolerability differences between routes are minimal. A Cochrane review of oral versus intramuscular B12 found only three randomised trials totalling 153 participants; one reported no treatment-related adverse events in either arm, and in another 2 of 30 participants (6.7%) in the oral group withdrew early because of adverse events — very low-quality evidence in the authors' assessment (Wang et al., Cochrane Database Syst Rev 2018).
What a high B12 blood level means
A markedly elevated serum B12 is usually not a toxicity finding. Because the body excretes the surplus, a high reading in someone supplementing is generally expected. A high reading in someone not supplementing is a different matter and is treated in clinical medicine as a marker worth investigating, since it can accompany liver disease, renal disease, or haematological conditions. The distinction is between the vitamin causing harm and the level pointing at something else.
The most common real harm is diagnostic
For most people, the realistic downside of B12 is not toxicological at all — it is that supplementing before testing normalises a serum B12 result and masks what was causing the deficiency. Pernicious anaemia, coeliac disease, and other malabsorptive conditions are diagnoses worth making in their own right, and a neurological deficiency that goes unidentified can become permanent (Stabler, N Engl J Med 2013).
Serum B12 is also an imperfect marker on its own; methylmalonic acid and homocysteine are the confirmatory tests the clinical literature relies on. The practical implication is not that B12 is dangerous — it is that "it can't hurt" is the wrong reason to take it, and testing first costs little.